The local actions of the inhibin-related peptides inhibin, activin, and follistatin in folliculogenesis, luteinization and atresia are reviewed. On the basis of in vitro data, it is concluded that (a) inhibin has a paracrine action positively regulating LH-induced androgen production by theca cells in addition to a peripheral role regulating FSH secretion; (b) activin has a negative paracrine action on LH-induced androgen production by theca cells; (c) activin, either alone or with FSH, has an autocrine action on granulosa cells, promoting differentiation during the preantral and early antral stages of folliculogenesis and preventing premature luteinization in the later stages of antral follicle development, leading overall to promotion and maintenance of the folliculogenic state of the follicle; and (d) fotlistatin modulates granulosa cell function in favor of luteinization or atresia, and its mechanism of action involves neutralizing the actions of activin by its binding properties and by a direct action of follistatin on progesterone metabolism by granulosa cells. A hypothesis for a role of activin in the acquisition of responsiveness of granulosa cells of preantral follicles to FSH is proposed.
INTRODUCTION
This review is concerned with the endocrine and paracrine control of folliculogenesis after reinitiation of growth of primordial follicles. Specifically, it will address the evidence for the autocrine and paracrine roles of the inhibinrelated peptides inhibin, activin, and follistatin (FSP) in folliculogenesis, luteinization, and atresia and the interactions with the pituitary gonadotropins FSH and LH.
The process of folliculogenesis in the ovary begins with the formation of primordial follicles each consisting of an oocyte in the resting meiotic prophase surrounded by a single layer of undifferentiated squamous granulosa cells [1] . Reinitiation and subsequent growth of the follicle through the various phases is characterized morphologically by the size of the oocyte, the numbers of layers of cuboidal granulosa cells, the presence and extent of the theca layer and antrum, and signs of atresia and it culminates in luteinization and ovulation or, more likely, atresia. While we have been well served by these morphological classifications of atresia, a functional model offers more insight into the physiology of follicular growth and development [1, 2] . It reflects the fact that after reinitiation of growth of primordial follicles, folliculogenesis is a continuous process, and that follicles are present in the ovary in a hierarchy according to their functional status. The functional model underlines the acquisition of receptivity to and necessity for gonadotropins, and also recognizes the role of autocrine and paracrine factors in folliculogenesis. For example, reinitiation of growth of primordial follicles and acquisition of dependence on FSH by preantral follicles are independent of gonadotropin action and therefore probably involve par- acrine and autocrine regulation. The subsequent recruitment of these follicles, which require gonadotropic support for continued growth and their selection to escape atresia to subsequently become dominant and ovulate, involves an interaction between the gonadotropins and local regulators. There is evidence mainly from in vitro studies that the inhibin-related peptides have actions in all the functional stages of folliculogenesis, including ovulation. The in vitro models have used granulosa cells representative of three broad stages of follicular development. Estrogen-treated, hypophysectomized, or intact immature rats provide granulosa cells that are essentially undifferentiated, having undergone extensive mitosis in preantral follicles in vivo. However, these cells are receptive to FSH [3] . Granulosa cells from follicles of estrogen-and FSH-treated immature rats [4] or from small-to-medium bovine follicles are partially differentiated-being receptive to gonadotropins but unable to luteinize spontaneously [5] . Finally, granulosa cells from follicles of estrogen-, FSH-, and hCG-treated immature rats [4] or from large preovulatory bovine follicles are fully differentiated and capable of spontaneous luteinization [6] . Theca cells from antral follicles have also been studied [7] [8] [9] .
The inhibin-related peptides include inhibin, activin, alpha N, transforming growth factor-3 (TGF-13), and a number of other peptides structurally related to TGF-13. This review will include only inhibin and activin, which are structurally related but functionally diverse with respect to FSH secretion, and FSP, which is functionally (but not structurally) similar to inhibin and is an activin binding protein.
The chemical and structural characteristics of these substances is reviewed elsewhere [10] .
A number of criteria should be fulfilled before a substance is designated autocrine or paracrine. Firstly, it should be demonstrated that there is local production of the regulator, e.g., by expression of its mRNA, net synthesis of the substance in vitro, and its immunochemical localization in cells. Secondly, its production should be regulated, e.g., by peripheral or local hormones. Thirdly, the putative regulator should have autocrine or paracrine actions on cells, possibly via cellular receptors. Fourthly, its action might be regulated at a local level by a binding protein, by its formation from a proform, or by its metabolism. Finally, its local action(s) should be demonstrated in vivo. The emphasis in this review will be on the last three criteriaexcept for FSP, where there are recent data concerning regulation of its production.
INHIBIN
There is substantial evidence for ovarian production of inhibin [see 10]. Inhibin is produced by the granulosa cells of the follicle (and by luteal cells in primates), and its production can be regulated at an endocrine (FSH, LH), paracrine (epidermal growth factor [EGF], TGF-a, interferony, androstenedione) and autocrine (insulin-like growth factor-1 [IGF-1], TGF-3, activin, FSP) levels. FSH, LH (at low doses), IGF-1, TGF-3, and activin can stimulate inhibin production by granulosa cells. EGF, TGF-oa, FSP, interferon-y, and high doses of LH negatively regulate inhibin production in the presence of FSH and other agents that increase cAMP levels [10] . Activin and interferon-y also stimulate basal inhibin production [11] [12] [13] . While there is evidence for intraovarian production of most of the regulators mentioned above, it remains to be established whether or not interferon-y is made by the ovarian follicle.
Intrafollicular Actions of Inhibin
An autocrine action of inhibin on estradiol production by rat granulosa cells has been described [14, 15] and is supported by the recent demonstration of inhibin-A binding sites on granulosa cells [16] . However, the inhibitory effect of inhibin on FSH-induced aromatase activity has not been confirmed by others [11, 17, 18] using both rat and bovine granulosa cells.
Inhibin does exert a potent stimulatory effect on LH-induced androgen production by rat and human theca cells, an effect that is attenuated by activin [7] [8] [9] . If confirmed in vivo, this would allow inhibin to enhance the supply of androgen substrate for the follicular production of estrogen, which could be particularly important for estrogenic follicles as they assume dominance. As the dominant follicle(s) emerges, the increasing production of inhibin and estradiol-170 could decrease FSH secretion and so restrict the growth of nondominant antral follicles. The dominant follicle could survive this decrease in the supply of FSH by the local action of factors such as IGF-1, activin, and inhibin, which would sensitize the follicular cells to gonadotropin stimulation (see below) thereby compensating for the decrease in FSH. On the other hand, nondominant follicles would not have these survival mechanisms and would therefore be destined to become atretic. With respect to the potential paracrine role of inhibin on theca androgen production, it is worth mentioning that immunization of animals against inhibin-which produces antibodies that recognize biologically active forms of inhibin-causes an increase in ovulation rate [19] . This suggests that either an action of inhibin on theca cells in vivo is not an absolute requirement for normal follicular development and ovulation or that the inhibin antibodies are not able to compromise an action of inhibin on the theca.
Woodruff et al. [16] have used injections of inhibin into the ovarian bursa of rats as an in vivo model system to study its potential paracrine role on folliculogenesis. Inhibin (1 Ipg) causes a small increase in the proportion of follicles > 350 pIm, particularly in the 350-500-[tm size class. The mechanism by which inhibin brings about this shift in follicular size classes is not known, but it could involve direct actions of inhibin on either theca [7, 9] or granulosa cells [16] . Further work is required to confirm and establish the presence of inhibin receptors on the ovarian follicular cells and to examine the regulation of these receptors.
In summary, there is evidence for a paracrine role of inhibin in the ovarian follicle-particularly on theca cells, but it is also likely that inhibin acts as a peripheral endocrine hormone regulating the secretion of FSH, and so influencing folliculogenesis through the hypothalamic-pituitary-ovarian axis.
ACTIVIN
Activin is a product of the granulosa cells, as determined from expression of the subunit mRNA in these cells and the isolation of activin from follicular fluid, but little is known about the temporal or regulatory aspects of its production [see 10]. A major difficulty in investigating the production of activin has been the lack of a specific and sensitive assay that can be applied to a large number of samples at any one time. Shintani et al. [20] recently described an RIA for activin that detects the highest concentrations of immunoreactivity in the ovary, although it was not sufficiently sensitive to measure activin in sera. Robertson et al. [21] have also described an activin RIA with limited cross-reaction with bovine 31-kDa and human recombinant 34-kDa inhibin (1-3%), and TGF-[31, Mullerian inhibiting substance, and FSP. However, in situations where there is likely to be a gross excess of inhibin over activin, such as in follicular fluid or in medium conditioned by granulosa cells, there may still be a substantial contribution of inhibin to the apparent activin immunoreactivity, thus requiring some preliminary purification steps prior to assay in order to obtain accurate measurements of the activin content of biological samples.
Intrafollicular Actions of Activin
Data from rat and bovine granulosa cell models support the hypothesis that activin regulates granulosa cell differ-entiation in an autocrine fashion and that this action of activin is related to the stage of granulosa cell differentiation and, hence, follicular maturity.
Essentially undifferentiated granulosa cells are obtained from diethylstilbestrol (DES)-treated immature rats, although they do have the capacity to respond to FSH. In the presence of FSH, activin enhances aromatase activity, estradiol production [4, 12, 17, 22] , LH binding sites [11] , and progesterone production [4, 11, 12, 22] , with no effects on the levels of these parameters in the absence of FSH. Activin also stimulates basal and FSH-induced inhibin production and steady-state levels of inhibin et and subunit mRNA [22, 23] (i.e., its own mRNA). Activin also increases the steady-state levels of FSP mRNA in rat granulosa cells in vitro [24] . Activin receptors have been localized on rat granulosa cells [16, 23, 25] , and Scatchard analysis has indicated a single class having a dissociation constant (Kd) of 140-340 pM [16, 25] , with the number of activin receptors being stimulated by FSH [25] . Activin treatment of granulosa cells from DES-treated immature rats results in a 4-fold increase in FSH receptor number, with no change in binding affinity [26] (Fig. 1) , confirming an earlier report [27] . Treatment with high doses of activin (100 ng/ml) prevents FSHinduced down-regulation of FSH receptor number, whereas at lower concentrations (3-30 ng/ml) activin enhances FSHinduced down-regulation of its receptor number by 20% [26] . Pretreatment of granulosa cells with activin for 24 h increases the responsiveness of the cells to FSH and LH, as shown by increases in aromatase activity and progesterone and immunoreactive inhibin production over and above control, in a manner that depends upon the dose of activin [26] . The mechanism of action of activin is likely to involve an increase in the production of cAMP [22, 23] , a conclusion supported by the observation that activin facilitates the stimulation by forskolin of aromatase activity, progesterone production, and inhibin production by granulosa cells from DES-treated immature rats [22] . These in vitro observations are consistent with activin as an autocrine regulator promoting folliculogenesis during the preantral or early antral stages of growth of follicles, since these data were all obtained using relatively undifferentiated granulosa cells from immature DES-treated rats.
The stimulatory influence of activin on FSH receptors (Fig. 1) , as a mechanism whereby preantral follicles may become responsive to FSH, is likely to be of particular importance. Little is known about the control of induction of FSH receptors on granulosa cells. FSH receptors first appear when the granulosa cells of primary follicles in the rat change in shape from squamous to cuboidal; by the time the follicle has reached the secondary stage, the granulosa cell has approximately 1500 FSH receptors, which it retains throughout the remainder of follicular development [1] . Relatively few agents are known to influence FSH receptor number. Apart from activin, FSH itself, cAMP stimulants or analogues, and EGF are the only other agents known to . The ability of activin to upregulate FSH receptors, particularly in the absence of FSH, distinguishes it from IGF-1 [28] . This suggests a unique role for activin in the acquisition and propagation of FSH receptors, a key event in preantral folliculogenesis. This proposition assumes that the granulosa cells either constitutively express or acquire receptors for activin prior to this important step in their differentiation. The expression of inhibin 3A mRNA in newly recruited rat follicles suggests that activin may be produced at this time [29] .
Activin effect on FSH receptors
Activin action in vitro on partially or fully differentiated granulosa cells is consistent with a role for this peptide in promoting folliculogenesis and preventing premature luteinization, which raises the possibility that activin is the luteinizing inhibitor originally proposed by Channing [30] . We reported an inhibitory effect of activin on FSH-stimulated progesterone production by granulosa cells from DEStreated immature rats [17] , but this observation was not confirmed [4, 12, 22] . Xiao [31] has shown recently, however, that although activin enhances the FSH-induced progesterone production by these granulosa cells, it decreases the amount of 20at-hydroxyprogesterone produced in the first 48 h of culture (Fig. 2) . Because there is an excess of 20oa-hydroxyprogesterone over progesterone at this time, total progestin is decreased. Miro et al. [4] examined the effect of activin on progesterone production by granulosa cells from rat ovarian follicles at different stages of differentiation. Partially differentiated granulosa cells were obtained from DES-and FSH-treated immature rats, in which activin stimulated basal progesterone production but inhibited FSH-stimulated progesterone production in vitro. When similar experiments were performed on granulosa cells obtained from DES-treated rats that had received both FSH and hCG in vivo and were therefore fully differentiated, both basal and FSH-stimulated progesterone production were inhibited by activin [4] . We have used bovine granulosa cells to study the effect of activin on luteinization. Recombinant human activin-A causes a time-and dose-dependent inhibitory effect on LH-induced production of progesterone and oxytocin production (indicators of luteinization' [6] ), by partially differentiated bovine granulosa cells in vitro [5] (Fig.  3) . Bovine activin A prevents the spontaneous luteinization of fully differentiated bovine granulosa cells in vitro [18] . These effects are reversible [18] , indicating that the inhibitory actions of activin are not due to a reduction in cell number. None of the actions of activin on granulosa cells function appear to involve any change in cell numbers, since the DNA content per well is not altered under any circumstances. Miro et al. [4] observed a decrease in thymidine uptake by granulosa cells in the presence of activin and FSH.
We conclude from these in vitro studies that activin affects the differentiation of granulosa cells in an autocrine manner and that its action depends on the stage of differentiation of the cells. It promotes differentiation of cells during the preantral and early antral stages of folliculogenesis and prevents premature luteinization of cells from the later stages of antral development, which leads overall to a promotion and maintenance of the folliculogenic state of the follicle. This hypothesis based on in vitro studies differs from that of Woodruff et al. [16] , which is based on in vivo studies. When Woodruff et al. injected 1-R1g doses of activin into the ovarian bursa of rats, they observed a reduction in the proportion of follicles > 350 m and a reduction in thymidine incorporation rates into granulosa cells and they concluded that activin is an atretogenic agent. There are several possible explanations for the discrepancy between the effects of activin in vivo and in vitro. We estimate that a single dose of 1 Izg of activin into the ovarian bursa could lead to final concentrations of the order of 50 000 ng/ml in bursal fluid [26] . We do not know the activin concentration in follicular fluid, although on the basis of the recovery of activin during purification, concentrations in the range of 50-250 ng/ml have been calculated. We have shown in vitro that at doses greater than 100 ng/ml, activin tends to decrease FSH-induced aromatase activity [12] . If high doses of activin depress aromatase in vivo, this could lead to low estrogen production and concomitant failure of folliculogenesis. An alternative explanation of the atretogenic effects of activin observed in vivo could be inhibition of androgen production by theca cells (see below), thereby depriving the follicle of androgen substrate for estrogen production. Further studies are obviously needed to resolve this discrepancy.
Exposure of rat and human theca cells to activin results in a dose-dependent reduction in LH-induced androstenedione production-an effect opposite to that caused by inhibin [7, 9] . Activin alone does not influence basal androstenedione production. This would constitute a paracrine action of activin in the ovarian follicle and, as mentioned above, could have important implications in the establishment of dominance of follicles. It should be noted that receptors for activin on theca cells have not been reported yet.
Overall, we believe the data are consistent with activin having both autocrine and paracrine actions within the ovarian follicle. The possibility that activin also plays a role as a peripheral regulator of FSH secretion has been investigated. The FSH releasing activity of activin in vitro has not been confirmed by an in vivo study since a single injection of a large dose of activin (50 jig) does not increase the serum FSH levels in adult male rats [32] . However, injection of activin-A (20 RIg) into immature estrogen-treated and intact female rats causes an increase in serum FSH [33] . Indirect evidence suggests, however, that the major nonsteroidal message coming from the ovary to the pituitary is inhibitory. The amount of activin in bovine follicular fluid seems quite low ( 5%) compared with that of inhibin. Administration of charcoal-treated follicular fluid reduces serum FSH concentrations in female rats [34] , and bilateral ovariectomy of eCG-primed immature female rats is followed by an increase in circulating FSH levels [35] . Furthermore, it is likely that activin is associated with a binding protein, FSP, which would neutralize its biological activity (see below). Taken together, these results indicate that the actions of follicular activin in vivo are more likely to be as a local regulator than as a peripheral FSH-releasing hormone.
FOLLISTATIN
FSP was first identified in bovine and porcine follicular fluid on the basis of its FSH-suppressing activity [36, 37] . FSP is now known to exist as a number of different isoforms that arise from the combination of two FSP precursors generated by alternate splicing, together with different degrees of glycosylation. FSP is coded by a single gene and the primary structure of FSP across species is highly conserved (> 97%) [see 10, 38] .
Although FSP is now known to be expressed in a number of different tissues, a major site of production is the granulosa cells in the ovary [see 10, 38] . Northern and S, nuclease analyses and in situ hybridization studies of the FSP mRNA and immunocytochemical localization of the FSP protein have shown FSP in granulosa cells and, under some circumstances, in luteal cells, but not in theca cells [see 10, 38] . FSP is secreted by granulosa cells from the rat [39, 40] and cow [41] , but not by theca interna tissue [41] .
FSP mRNA production by granulosa cells is regulated by FSH but not LH in vivo and in vitro [10, 38] . We have used cultures of granulosa cells from DES-treated immature rats [24] to show that FSH has dose-and time-dependent stimulatory effects on steady-state levels of FSP mRNA, whereas LH, prolactin, growth hormone, and IGF-1 have little or no effect. Activin has a biphasic effect on FSP mRNA, being inhibitory at low doses and stimulatory at high doses on basal as well as on FSH-stimulated FSP mRNA levels (Fig. 4) . EGF II --n and cAMP [41] , but not by LH [39, 41] , confirming that FSP production is likely to be FSH-but not LH-dependent. No explanation can be given for the lack of effect of LH but not of cAMP on FSP production.
The cyclic changes in FSP mRNA and its protein have been described in the rat ovary during the estrous cycle [42] . Neither the mRNA nor the protein is detectable in primordial or in primary follicles. FSP mRNA is first detected in granulosa cells of secondary follicles and then becomes more abundant as the follicle forms an antrum, being expressed in the whole granulosa cell layer. The strongest signal is found in preovulatory follicles and newly formed corpora lutea. Expression of FSP protein is confined to healthy dominant preovulatory follicles and a subpopulation of tertiary follicles in animals entering estrus. Atretic follicles show no immunoreactive follistatin in the granulosa cells, although there is occasionally evidence of expression of FSP mRNA. Similar to the rat, the bovine FSP mRNA signal increases as folliculogenesis progresses, with the stronger signal being observed in preovulatory bovine follicles [43] .
Intrafollicular Actions of Follistatin
FSP modifies FSH action on undifferentiated granulosa cells from DES-treated immature rats. It causes a dose-dependent inhibition of aromatase activity and inhibin production and enhances progesterone production induced by FSH [12, 22] . FSP has no effects in the absence of FSH and does not influence either basal or FSH-stimulated cAMP production. These results from the rat model are supported by data in which it was found that three forms of bovine FSP (31, 35, and 39 kDa) enhance and prolong oxytocin and progesterone production by LH-stimulated partially differentiated bovine granulosa cells [5] . FSP has no detectable effects on oxytocin and progesterone production by fully differentiated bovine granulosa cells undergoing spontaneous luteinization [5] . These effects of FSP are consistent with changes in hormone output of granulosa cells during luteinization and atresia, opposite to the effects of activin on these granulosa cells in culture. We showed subsequently that FSP antagonizes the actions of activin on granulosa cells in culture. FSP reverses the enhancing effects of activin on FSH-stimulated steroidogenesis and inhibin production [22] , inhibits activin-induced FSH receptor number [26] , and inhibits activin-induced basal inhibin production by undifferentiated rat granulosa cells [44] . Furthermore, FSP added to cultures of partially differentiated bovine granulosa cells treated with activin and LH reverses the inhibitory effect of activin on progesterone and oxytocin production, with a significant increase in the output of these hormones above control levels using the 35-and 39-kDa forms of bovine FSP [5] (Fig. 3) .
From these data, we hypothesize that FSP modulates granulosa cell function in an autocrine fashion, that its actions favor the process of luteinization or atresia, and that its mechanism of action involves neutralizing the effects of activin. FSP has also been shown to antagonize the effects of activin in the pituitary cells [45, 46] and embryonic mesoderm [47] , and it has been shown subsequently that FSP is an activin binding protein [40] . Several studies have investigated the nature of the binding of activin to FSP. Shimonaka et al. [48] concluded, by means of a double ligandblotting technique that activin-A has two binding sites for FSP, whereas inhibin-A has only one binding site for FSP; these researchers hypothesize that FSP binds activin and inhibin through the common 3 subunit. A molar ratio of FSP:activin -2.2:1 is required for inhibition of development of amphibian mesoderm [47] , and 2.9:1 for inhibition of pituitary FSP mRNA induced by activin [46] . On the other hand, Kogawa et al. [45] showed that activin binds to FSP to form an equimolar complex having neither stimulatory nor inhibitory activity on FSH secretion by the pituitary. We have used the capacity of FSP to inhibit the stimulatory effects of activin on basal inhibin production by rat granulosa cells as a model to study the interaction, and we have concluded that activin binds FSP in a molar ratio 2:1 and with a Kd of about 0.1 nM (range 0.07-0.24 nM) [44] . This compares well with a reported Kd of about 0.6 nM for activin binding to rat follistatin [40] . Such a high affinity interaction would be required for FSP binding of activin to have physiological relevance if the binding of activin to its own receptors is in the low nM range [see 49] . Taken together, the data suggest that at least two FSP molecules are required to neutralize the bioactivity of one molecule of activin.
It is also possible that FSP may have direct actions on granulosa cells independent of its activin binding activity. This assertion is based on the effects of FSP on progesterone production and metabolism by undifferentiated rat granulosa cells [12, 22, 31] (Fig. 2) . FSP stimulates both progesterone [12] and 20ct-hydroxyprogesterone production induced by FSH in granulosa cells from DES-treated rats [31] . In contrast, activin stimulates progesterone, but decreases 20ot-hydroxyprogesterone production in this model [31] . Because there is an excess of 20a-hydroxyprogesterone over progesterone produced by rat granulosa cells under these culture conditions, FSP causes an overall increase in total progestin (progesterone plus 20ao-hydroxyprogesterone), whereas activin causes a decrease over 48 h in culture. We also observed that FSP enhances the stimulatory action of forskolin on progesterone production by rat granulosa cells, but does not influence the effect of forskolin on either aromatase activity or inhibin production [22] . In contrast, activin enhances all three parameters stimulated by forskolin [22] . This suggests a direct action of FSP on progesterone production and/or metabolism by rat granulosa cells that is independent of activin. To date there have been no reports of receptors for FSP, although FSP does interact with the heparain sulphate side-chains of proteoglycans on the surface of rat granulosa cells [50] . Whether been no reports of receptors for FSP, although FSP does interact with the heparan sulphate side-chains of proteoglycans on the surface of rat granulosa cells [50] . Whether or not this forms part of a direct action of FSP on the cell is not known. Nevertheless, a stimulatory effect of FSP on progestin production would be facilitated by the continued expression and production of FSP after the gonadotropin surge and ovulation, when the levels of inhibin 3 subunit mRNA (and presumably activin protein) produced by granulosa cells fall sharply. The effects of FSP on theca cell function have not been reported.
On the basis of in situ expression of FSP mRNA and FSP protein in follicles during the estrous cycle of the rat, Nakatani et al. [42] proposed that (a) FSP promotes folliculogenesis by its ability to bind activin and prevent activin from exerting the atretogenic action described by Woodruff et al. [16] and (b) FSP may have a role in luteinization by stimulating progesterone production. The in vitro data reviewed above are consistent with the proposal that FSP facilitates luteinization, but is not consistent with the proposal that it promotes folliculogenesis. Further experimentation will be required to resolve these differences in interpretation of the roles of FSP and activin. In particular, it will be important to examine the temporal relationships between the production of activin and FSP and how this relationship changes with follicular maturation, atresia, and luteinization.
FSP has been measured in peripheral blood of humans [51] and sheep [52] , suggesting that it might act as a circulating hormone or as a binding protein for activin in peripheral blood. However, we have observed that the concentrations of FSP vary very little across the estrous cycle of the ewe, and after ovariectomy there is little or no reduction in the peripheral concentrations of FSP [52] . The source(s) of circulating FSP and its role and regulation require further investigation.
In summary, FSP production by granulosa cells is regulated by FSH and activin; its mRNA levels change with folliculogenesis and atresia; and it would appear to be an activin binding protein, although direct effects of FSP on granulosa cells cannot be dismissed.
CONCLUSIONS
Evidence has been presented for a local regulatory role for inhibin, activin, and FSP in the control of folliculogenesis at different stages from differentiation of preantral follicles to initiation of luteinization. The in vitro data are consistent with two hypotheses on the control of folliculogenesis, viz., that (a) local regulators are involved in the transition of follicles from gonadotropin-independent to gonadotropin-dependent and the follicles' subsequent differentiation; and (b) a feedback mechanism involving estradiol, inhibin, and the gonadotropins-FSH in particular-is involved together with local regulators in determining the final number of selected antral follicles that become dominant and ovulate.
Both inhibin (positive) and activin (negative) have paracrine actions on theca cell production of androgen induced by LH. This has implications for the availability of substrate for estrogen production by follicles, which is important in the processes of selection and dominance. An unlimited supply of androgen substrate would require continued exposure of theca cells to LH and inhibin but protection from the actions of activin (by FSP?) and estradiol (which also inhibits androgen synthesis by theca cells) [53] . The actions of FSP on theca cell function have not been published, nor have there been any reports of the actions of the inhibin-related peptides on the production of TGFot/EGF or TGF-3 by theca cells or on the induction of theca cells during folliculogenesis.
It is clear from the in vitro data that activin has the capacity to regulate differentiation of the granulosa cells in an autocrine fashion and that this action of activin depends on the state of differentiation of the cells. A hypothesis is proposed for a role for activin in the induction of FSH receptors in undifferentiated granulosa cells and the consequent acquisition of responsiveness to (and eventually dependence on) FSH (Fig. 5) . It is proposed that activin, produced by granulosa cells of preantral follicles lacking FSH receptors, acts on these same cells to induce receptors for FSH. FSH then acts on the cells to stimulate production of more activin and the activin receptor, and FSH and activin together further enhance FSH receptor number in partially differentiated cells. FSH and activin also induce FSP production, which modulates the action of activin and may have actions on the granulosa cell, independent of its activin binding properties. This model also implies that some differentiating actions of FSH on granulosa cells may be mediated by activin, which would explain why FSP inhibits FSH-induced differentiation of the cells in vitro.
Activin, by virtue of its stimulatory action on cAMP production, facilitates differentiation of granulosa cells, particularly in the presence of FSH and, subsequently, LH. Although activin stimulates progesterone production by undifferentiated granulosa cells, it inhibits total progestin production at all stages of differentiation, in contrast to FSP, which stimulates progestin production (Fig. 2) . Taken together with the stimulatory effects in vitro of activin on cAMP, aromatase activity, estradiol production, and gonadotropin receptors, this implies that activin promotes differentiation of granulosa cells but prevents luteinization and atresia. In contrast, FSP appears to have the opposite effects to activin in vitro, because it inhibits the effects of activin and stimulates progestin production.
Many aspects of these hypotheses concerning the actions of inhibin, activin, and FSP require confirmation and further testing. For example, there are a number of different forms of each peptide that are capable of being produced-e.g., two inhibins, three activins, -six FSPs-and the separate roles of these different forms, if any, have not been investigated. Factors controlling production of the peptides and assembly of the inhibin subunits need addressing, as do methods to measure activins and the various forms of the other peptides. Finally, evidence for intragonadal roles for these peptides needs to be obtained in vivo, and the in vivo data that do exist on the roles of these peptides as local regulators need to be reconciled with the in vitro evidence.
